Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant
morbidity, with mortality exceeding 30% in the first two days.The initial injury is related
to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with
the release of iron. Iron has been shown to increase the incidence of cerebral edema,
ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic
chelator, creates a stable complex with free iron thus preventing the formation of iron
related free radicals.
This trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment
of aSAH for patients that are admitted to the hospital at the University of Michigan or
Peking University Health Science Center. Eligible participants will be enrolled and
randomized to 1 of 2 doses of Deferoxamine or placebo (saline). Information regarding the
patients will be collected and followed for up to 6 months post discharge.
Phase:
Phase 2
Details
Lead Sponsor:
Aditya S. Pandey, MD
Collaborator:
Michigan Medicine PKUHSC Joint Institute for Translational & Clinical Research